1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Hepatorenal Syndrome- Market Insight, Epidemiology and Market Forecast -2030

Hepatorenal Syndrome- Market Insight, Epidemiology and Market Forecast -2030

  • February 2021
  • 125 pages
  • ID: 6028043
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

‘Hepatorenal Syndrome (HRS) – Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the Hepatorenal Syndrome (HRS), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Hepatorenal Syndrome (HRS) market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted HRS symptoms market size from 2017 to 2030 segmented by seven major markets. The report also covers current Hepatorenal Syndrome (HRS) symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017–2030

Hepatorenal Syndrome (HRS) Disease Understanding and Treatment Algorithm

Hepatorenal Syndrome (HRS) Overview
Hepatorenal syndrome (HRS) is a serious complication of liver cirrhosis with a critically poor prognosis. The pathophysiological hallmark is severe renal vasoconstriction, resulting from complex changes in splanchnic and general circulations as well as systemic and renal vasoconstrictors and vasodilators. HRS always develops in the setting of advanced circulatory dysfunction, and it is always accompanied by ascites and usually by hyponatremia.

HRS definition has been updated recently by the International Ascites Club (IAC) under Kidney Disease Improving Global Outcomes (KDIGO) acute kidney injury (AKI) classification. Recent changes in terminology have led to acute or type I HRS being referred to as AKI-HRS and chronic or type II HRS as chronic kidney disease (CKD)-HRS.
The modification of AKI definition has also led to a change in HRS’s diagnostic criteria. The new diagnostic criteria are based on AKI stages, and there is no need to reach a specific serum creatinine threshold. As per these new criteria, treatment with vasoconstrictors and albumin for HRS management will be started at lower serum creatinine values, with expected higher response rates.

The clinical implications of the newly proposed diagnostic criteria based on the dynamic, serial changes in serum Cr conforming to Acute Kidney Injury Network (AKIN), KDIGO clinical practice guidelines for AKI, Acute Dialysis Quality Initiative (ADQI), and IAC classification systems and revised recommendations of IAC remain unclear. These new diagnostic criteria will certainly result in more hospitalized patients with cirrhosis deemed to have AKI, but whether this will result in earlier treatment and improved outcomes is not known. Renal biomarkers, particularly associated with metabolomic profiling, may ultimately prove to be helpful in more precisely establishing a diagnosis of HRS, but they currently appear to be of limited, practical clinical value.

Hepatorenal Syndrome (HRS) Diagnosis and Treatment
It covers the details of conventional and current medical therapies, and diagnosis available in the Hepatorenal Syndrome (HRS) market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.
The Hepatorenal Syndrome (HRS) market report gives a thorough understanding of HRS symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides HRS symptoms of treatment algorithms and treatment guidelines for HRS symptoms in the US, Europe, and Japan.

Hepatorenal Syndrome (HRS) Epidemiology
The epidemiology division’s Hepatorenal Syndrome symptoms provides insights about the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Hepatorenal Syndrome (HRS) epidemiology segmented as the Total Incident cases of Hepatorenal Syndrome (HRS), Diagnosed Incident Cases of Hepatorenal Syndrome (HRS), and Type-specific cases of Hepatorenal Syndrome (HRS). The report includes the Incident scenario of HRS symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Hepatorenal Syndrome (HRS) Epidemiology
The epidemiology segment also provides the Hepatorenal Syndrome (HRS) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total 7MM incident cases of Hepatorenal Syndrome (HRS) were 282,616 in 2020.

Hepatorenal Syndrome (HRS) Drug Chapters
The drug chapter segment of the Hepatorenal Syndrome (HRS) report encloses the detailed analysis of HRS marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Hepatorenal Syndrome (HRS) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
The mainstay of treatment remains vasopressor therapy with albumin to reverse splanchnic vasodilation and improve RBF. Vasoconstrictor therapy cause constriction of splanchnic vessels, resulting in increasing the effective circulating blood volume, which increases renal perfusion and glomerular filtration. Vasoconstrictors are often combined with albumin to improve their clinical benefits. Vasoconstrictors used for HRS management are terlipressin, noradrenaline, and the combination of midodrine + octreotide.
Products detail in the report…
Hepatorenal Syndrome (HRS) Emerging Drugs
BIV201 (BioVie) is a potent vasoconstrictor and has shown efficacy for reducing portal hypertension. According to the company, continuous infusion dosing a new treatment paradigm terlipressin given by continuous infusion is better tolerated than intravenous boluses in type 1 HRS treatment. Moreover, it is effective at lower doses. The drug has also received Orphan Drug designations for ascites and HRS with potential 7 years market exclusivity, which will give the advantage to occupy good market share.
Products detail in the report…

Hepatorenal Syndrome (HRS) Market Outlook
The Hepatorenal Syndrome (HRS) market outlook of the report helps build the detailed comprehension of the historic, current and forecasted Hepatorenal Syndrome (HRS) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of Hepatorenal Syndrome (HRS) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to the analyst, Hepatorenal Syndrome (HRS) market in 7MM is expected to change in the study period 2017–2030.

Key Findings
This section includes a glimpse of the Hepatorenal Syndrome (HRS) market in 7MM. The market size of HRS in the seven major markets was found to be USD 589.67 million in 2020 and market is estimated to increase at a CAGR of 1.17% for the study period (2017–2030).

The United States Market Outlook
This section provides a total of Hepatorenal Syndrome (HRS) market size and market size by therapies in the United States.
The United States accounts for the highest HRS market size compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
As terlipressin is currently not available in the USA, other vasoconstrictors like norepinephrine, midodrine, and octreotide, are used to treat HRS. Norepinephrine, a catecholamine with predominantly alpha-adrenergic activity, is an inexpensive alternative and widely used as an infusion for HRS treatment. Midodrine (an ?1-agonist drug) is usually administered in combination with octreotide (a somatostatin analog) and albumin, and it represents the current standard-of-care in the United States.

The administration of norepinephrine plus albumin has been investigated in the treatment of HRS-1. It was shown to be as effective as terlipressin in the HRS treatment in several trials. Currently, norepinephrine in treating HRS is limited by the need for a central venous line and continuous monitoring, thus rendering the treatment unfeasible outside intensive care units.

EU-5 Countries: Market Outlook
The total Hepatorenal Syndrome (HRS) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Terlipressin is the most common vasopressor used and acts on the V1 receptors on vascular smooth muscle cells. Despite the increasing body of evidence supporting its use, Terlipressin has not been approved for use in the United States yet. It is currently marketed in Europe for the treatment of HRS.

Japan Market Outlook
The total Hepatorenal Syndrome (HRS) market size and market size by therapies in Japan are also mentioned.

Hepatorenal Syndrome (HRS) Drugs Uptake
This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017–2030. The analysis covers Hepatorenal Syndrome (HRS) market uptake by drugs; patient uptake by therapies; and drug sales.
This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Hepatorenal Syndrome (HRS) Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Hepatorenal Syndrome (HRS) key players involved in developing targeted therapeutics.
Major players include Terlipressin (Mallinckrodt) and BIV201 (BioVie) being assessed as potential therapies to be available in the market in the coming future.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Hepatorenal Syndrome (HRS) emerging therapies.
Reimbursement Scenario in Hepatorenal Syndrome (HRS)
While many individuals wait until their claim has been denied before seeking the services of a Social Security attorney, the patient should consider retaining legal representation before submitting the initial application. By working with an attorney or advocate, the patient will ensure that patient’s claim has sufficient supportive medical evidence and that it will be processed through the Compassionate Allowances program. An attorney will do his or her best to make sure that the patient receives Social Security Disability benefits as quickly as possible and will help the patient avoid the lengthy disability appeal process
KOL- Views
To keep up with current market trends, we take KOLs and SME’s opinion working in Hepatorenal Syndrome (HRS) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or the Hepatorenal Syndrome (HRS) market trend. This will support the clients in potential upcoming novel treatment by identifying the market’s overall scenario and the unmet needs.

Competitive Intelligence Analysis
We perform Competitive & Market Intelligence analysis of the Hepatorenal Syndrome (HRS) Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
• The report covers the descriptive overview of Hepatorenal Syndrome (HRS), explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
• Comprehensive insight has been provided into the Hepatorenal Syndrome (HRS) epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Hepatorenal Syndrome (HRS) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Hepatorenal Syndrome (HRS) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Hepatorenal Syndrome (HRS) market

Report Highlights
• In the coming years, Hepatorenal Syndrome (HRS) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Hepatorenal Syndrome (HRS) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for HRS. The launch of emerging therapies will significantly impact the Hepatorenal Syndrome (HRS) market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for HRS.

• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Hepatorenal Syndrome (HRS) Report Insights
• Patient Population
• Therapeutic Approaches
• Hepatorenal Syndrome (HRS) Pipeline Analysis
• Hepatorenal Syndrome (HRS) Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Hepatorenal Syndrome (HRS) Report Key Strengths
• 10 Years Forecast
• 7MM Coverage
• Hepatorenal Syndrome (HRS) Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market

• Drugs Uptake

Hepatorenal Syndrome (HRS) Report Assessment
• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions

Market Insights:
• What was the Hepatorenal Syndrome (HRS) Market share (%) distribution in 2017 and how it would look like in 2030?
• What would be the Hepatorenal Syndrome (HRS) total market Size as well as market Size by therapies across the 7MM during the forecast period (2017–2030)?
• What are the market’s key findings across 7MM and which country will have the largest Hepatorenal Syndrome (HRS) market Size during the forecast period (2017–2030)?
• At what CAGR, the Hepatorenal Syndrome (HRS) market is expected to grow by 7MM during the forecast period (2017–2030)?
• What would be the Hepatorenal Syndrome (HRS) market outlook across the 7MM during the forecast period (2017–2030)?
• What would be the Hepatorenal Syndrome (HRS) market growth till 2030, and what will be the resultant market Size in the year 2030?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:
• What are the disease risk, burden, and unmet needs of the Hepatorenal Syndrome (HRS)?
• What is the historical Hepatorenal Syndrome (HRS) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan?
• What would be the forecasted patient pool of Hepatorenal Syndrome (HRS) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan?
• What will be the growth opportunities in the 7MM concerning the patient population about Hepatorenal Syndrome (HRS)?
• Out of all 7MM countries, which country would have the highest incident population of Hepatorenal Syndrome (HRS) during the forecast period (2017–2030)?
• At what CAGR the population is expected to grow by 7MM during the forecast period (2017–2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
• What are the current options for the treatment of Hepatorenal Syndrome (HRS)?
• What are the current treatment guidelines for treating Hepatorenal Syndrome (HRS) in the USA, Europe, and Japan?
• What are the Hepatorenal Syndrome (HRS) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
• How many companies are developing therapies for the treatment of Hepatorenal Syndrome (HRS)?
• How many therapies are developed by each company for the treatment of Hepatorenal Syndrome (HRS)?
• How many emerging therapies are in the mid-stage and late stages of development to treat Hepatorenal Syndrome (HRS)?
• What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hepatorenal Syndrome (HRS) therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hepatorenal Syndrome (HRS) and their status?
• What are the key designations that have been granted for the emerging therapies for Hepatorenal Syndrome (HRS)?
• What are the global historical and forecasted market of Hepatorenal Syndrome (HRS)?

Reasons to buy
• The report will help in developing business strategies by understanding trends shaping and driving the Hepatorenal Syndrome (HRS) market
• To understand the future market competition in the Hepatorenal Syndrome (HRS) market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Hepatorenal Syndrome (HRS) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Hepatorenal Syndrome (HRS) market
• To understand the future market competition in the Hepatorenal Syndrome (HRS) market

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Global Peptic Ulcer Drugs Industry

  • $ 4950
  • April 2021
  • 136 pages

Abstract: - Global Peptic Ulcer Drugs Market to Reach $5.9 Billion by 2027 - Amid the COVID-19 crisis, the global market for Peptic Ulcer Drugs estimated at US$4.9 Billion in the year 2020, is projected ...

  • World
  • China
  • Digestive System Disorder
  • Industry analysis

Company Analysis: Takeda $ 3000 January 2021


ref:plp2021

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on